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Cancer invasion is regulated by cell surface proteinases and adhesion molecules. Interaction between specific cell surface molecules
such as urokinase plasminogen activator receptor (uPAR) and integrins is crucial for tumour invasion and metastasis. In this study, we
examined whether uPAR and b1 integrin form a functional complex to mediate signalling required for tumour invasion. We assessed
the expression of uPAR/b1 integrin complex, Erk signalling pathway, adhesion, uPA and matrix metalloproteinase (MMP) expression,
migration/invasion and matrix degradation in a colon cancer cell line in which uPAR expression was modified. Antisense inhibition of
the cell surface expression of uPAR by 50% in human colon carcinoma HCT116 cells (A/S) suppressed Erk-MAP kinase activity by
two-fold. Urokinase plasminogen activator receptor antisense treatment of HCT116 cells was associated with a 1.3-fold inhibition of
adhesion, approximately four-fold suppression of HMW-uPA secretion and inhibition of pro-MMP-9 secretion. At a functional level,
uPAR antisense resulted in a four-fold decline in migration/invasion and abatement of plasmin-mediated matrix degradation. In empty
vector-transfected cells (mock), uPA strongly elevated basal Erk activation. In contrast, in A/S cells, uPA induction of Erk activation
was not observed. Urokinase plasminogen activator receptor associated with b1 integrin in mock-transfected cells. Disruption of
uPAR–b1 integrin complex in mock-transfected cells with a specific peptide (P25) inhibited uPA-mediated Erk-MAP kinase pathway
and inhibited migration/invasion and plasmin-dependent matrix degradation through suppression of pro-MMP-9/MMP-2 expression.
This novel paradigm of uPAR–integrin signalling may afford opportunities for alternative therapeutic strategies for the treatment of
cancer.
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Urokinase plasminogen activator receptor (uPAR) is the cellular
receptor for urokinase, a serine proteinase that is constitutively or
inducibly secreted by most uPAR-expressing cells (Chapman et al,
1999). Urokinase plasminogen activator receptor/CD87 is a
glycoprotein (Mr 35000–65000) anchored to the plasma mem-
brane by a glycosyl phosphatidylinositol (GPI) linkage (Blasi,
1999). Receptor-bound uPA converts plasminogen to plasmin that
mediates pericellular proteolysis of extracellular matrix proteins.
Urokinase plasminogen activator receptor is overexpressed by
some cancer cells and its expression has been shown to correlate
with poor prognosis of many cancers (Dano et al, 1999). In murine
tumour models, expression or administration of uPAR antagonists
has a marked inhibitory effect on the metastatic ability of cancer
cells (Crowley et al, 1993) and on the growth of the primary
tumour (Min et al, 1996). In a number of cancers, the expression of
uPAR is required for invasive phenotype (Cohen et al, 1991).
Overexpression of uPAR in human osteosarcoma cells facilitates
matrix degradation (Kariko et al, 1993). Rats injected with breast
cancer cells overexpressing uPAR, develop significantly large
primary and metastatic tumours compared to control rats
receiving breast cancer cells with lower numbers of uPAR (Xing
and Rabbani, 1996). Down-regulating uPAR expression by
antisense treatment inhibits glioma invasion through Matrigel
(Mohan et al, 1999b) and invasion and metastasis by non-small-
cell lung cancer cell line (Mohan et al, 1999a). Similarly, injection
of adenovirus-uPAR construct into U87-MG tumours in nude mice
caused regression of tumours (Ganesh et al, 1994). In colon cancer,
a high uPAR expression portends a low 5-year survival rate
(Ganesh et al, 1994). These findings clearly suggest that uPAR may
be an important target in preventing cancer spread.
Urokinase plasminogen activator receptor has been reported to
associate with many signalling molecules and to mediate signal
transduction (Yebra et al, 1996; Aguirre Ghiso et al, 1999a; Wei
et al, 1999). As uPAR has no transmembrane structure, the exact Received 25 November 2002; revised 7 May 2003; accepted 9 May 2003
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smechanism of uPAR-mediated cellular signalling remains un-
known. The existence of one or more hypothetical ‘transmembrane
adapter molecules’ that couples uPAR to other signalling molecules
inside the cells has been proposed (Wei et al, 1999). It has been
shown that b1, b2 and b3 integrin receptors interact with uPAR
(Bohuslav et al, 1995; Todd and Petty, 1997; Xue et al, 1997;
Degryse et al, 2001; Wei et al, 2001). The uPAR–integrin
interaction is crucial as many integrin receptors activate intracel-
lular signals coupled to pathways used by receptor and non-
receptor tyrosine kinases (Wary et al, 1996, 1998). Integrin and
receptor tyrosine kinases-mediated signals may complement each
other to activate fully cell survival and proliferation pathways
(Miyamoto et al, 1996; Yamada and Geiger, 1997). Recently, we
have shown that the cytoplasmic domain of avb6 integrin interacts
with Erk and that interaction is essential to maintain tumour
growth in mice (Ahmed et al, 2002a).
The uPAR–integrin complex can be specifically disrupted by a
17-amino–acid peptide sequence (P25), isolated from a phage
peptide library (Wei et al, 1996). The P25 peptide decreased uPAR-
mediated adhesion of embryonic kidney 293 cells to vitronectin, a
substrate for uPAR when associated with integrins (Wei et al,
1996). Consistent with this observation, P25 peptide decreased
adhesion of metastatic MDA-MB-231 breast cancer cell line to
vitronectin, but increased its adhesion to fibronectin (van der
Pluijm et al, 2001). Moreover, stable transfected MDA-MB-231
cells that overexpress P25 showed a significant reduction in
tumour progression in bone, and was consistent with reduced
tumour progression of MDA-MB-231 cells to bone by continuous
administration of P25 peptides (van der Pluijm et al, 2001). These
data suggest that adhesive and proteolytic events are tightly
associated in cancer cells and functional uPAR–integrin com-
plexes are involved in the processes.
In this study, we have investigated the mechanism by which a
reduction in cell surface expression of uPAR impairs uPA/plasmin-
mediated matrix degradation and invasion. We demonstrate that
suppression of uPAR expression in a colon HCT116 cell line results
in reduced activation of the Erk-MAP kinase pathway, leading to
reduced HMW-uPA secretion, reduced adhesion, migration/
invasion and plasminogen-dependent matrix degradation. Our
result also demonstrates that downregulation of uPAR results in
loss of uPAR/b1 integrin complex, resulting in abatement
of uPA signalling through the uPAR/b1 integrin complex. Similar
scenario is observed when uPAR/b1 integrin complex is disrupted
by a specific P25 peptide. Even though the role of
uPA/uPAR/integrin signalling in maintaining cell adhesion and
proliferation has been described previously (Aguirre Ghiso et al,
1999b), our data for the first time establishes the role of
this interaction in maintaining the invasive phenotype of colon
cancer cells.
MATERIALS AND METHODS
Antibodies and reagents
Monoclonal antibody against uPAR (3936) was obtained from
American Diagnostica (Greenwich, USA), antiphospho-Erk from
New England Biolab (MA, USA) and pan-Erk from Santa Cruz (CA,
USA). The monoclonal antibodies against integrin a1 (FB12), a2
(PIE6), a3 (PIB5), a4 (PIH4), a5 (PID6), a6 (CLB-701), av (LM 142)
and b1 (P5D2), were from Chemicon International (CA, USA).
Phycoerythrin-conjugated goat anti-mouse IgG was obtained from
Chemicon International (CA, USA) and peroxidase-conjugated
goat anti-mouse antibody from Bio-Rad (CA, USA). Amiloride,
1,10-phenanthroline and Trasylol were purchased from Sigma (St
Louis, USA). The Glu-plasminogen (glu-Plg) was from Calbiochem
(Darmstadt, Germany) and Ukidan was obtained from Serono
(Sydney, Australia).
Peptide synthesis
Two synthetic peptides were used in the study: P25, AES-
TYHHLSLGYMYTLN-NH2 and a peptide with the exact composi-
tion of amino acids of P25 but in scrambled sequence order (Scp),
NYHYLESSMTALYTLGH. Peptides were synthesised by Auspep
Pty Limited (Parkville, Australia) and had a purity of greater than
95% as determined by reversed-phase HPLC.
Preparation of uPAR-antisense constructs
The 50 uPAR cDNA fragments were obtained from the 1.144kb
human uPAR cDNA. The fragment (XbaI/BamHI, 498bp) of the
uPAR cDNA was subcloned into the expression vector pDR2
(Clontech) in an antisense orientation. The orientation of the
antisense insert in the vector was confirmed by DNA sequencing.
This was determined from the vector template using standard dye-
labelled primer protocols from Applied Biosystems and a model
373A automated DNA sequencing system (Applied Biosystems,
Inc., CA, USA). Analysis of DNA sequencing data and alignments
of DNA sequences were performed using the MacVector program
(Version 4.0.1, dated 1992, International Biotechnologies, Inc.,
New Haven, USA).
Transfection and selection of the HCT116 clones
Cells (2 10
6) were plated per 100mm dish in Dulbecco’s modified
Eagle’s medium (DMEM) with 10% FCS for 16h and processed
according to the protocol provided by Stratagene (CA, USA). The
cells were transfected with 20mg of either antisense vector or
empty vector using the calcium phosphate precipitation method.
After incubation at room temperature for 20min, the suspension
was added dropwise to the above dishes and the cells cultured for
further 48h and then kept in DMEM with G418 and/or
hygromycin. After 5 days, the antibiotic-resistant clones were
isolated, subcultured and passaged. More than 400 antibiotic-
resistant colonies were obtained and screened for either antisense-
uPAR or full-length uPAR integration by Southern blot analysis.
The clone with the most potent suppression of uPAR XT11’17 (A/
S) was used for further studies in comparison to the parental
HCT116 [wild-type (WT)] and an empty-vector-transfected clone
(mock), XT0.
Southern blot analysis
High molecular weight DNAs extracted from transfected or
untransfected cells were electrophoresed, and further processed
(Ausubel et al, 1987). The uPAR cDNA was labelled with (a-
32P)-
dCTP and hybridisation was carried out.
Flow-cytometric analyses
Monolayer cultures of HCT116 cell lines (WT, mock and A/S) were
washed twice with phosphate-buffered saline (PBS), harvested with
trypsin-versene (CSL Biosciences, Australia) and 10
6 cells were
incubated with primary antibody for 30min at 41C and washed
twice with phosphate buffered saline PBS. Cells were stained with
secondary antibody conjugated with phycoerythrin for 20min at
41C, washed twice with PBS and then resuspended in 0.5ml PBS
prior to FACScan analysis (Becton Dickinson, NJ, USA). All data
were analysed using Cell Quest software (Becton-Dickinson, NJ,
USA). Results are expressed as mean fluorescence units for
triplicate determinations.
Cell proliferation and adhesion assays
In all, 1 10
4 (proliferation assay) or 1 10
5 (adhesion assay)
mock and A/S HCT116 cells were plated on a specific protein-
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scoated wells of a 96-well plate (Nunc, USA). For proliferation
assay, after 24h incubation at 371C, MTT (5mgml
 1) was added
and cells were further incubated for 2h. After removing the
medium from the top, cells were solubilised in 1% SDS and
absorbance was measured at 595nm with a Vmax plate reader (Bio-
Rad, CA, USA).
For adhesion assays, cells were incubated in their respective
protein-coated plates at 371C for 90min and then washed
extensively with PBS to remove nonadhering cells. The adherent
cells were fixed with 100% methanol for 5min at room
temperature, stained with 0.5% crystal violet for 15min and then
solubilised with 0.1% SDS. Absorbance at 595nm was measured
with Vmax plate reader (Bio-Rad, CA, USA).
Erk-MAP kinase assay
Monolayer cultures of colon cancer cell lines were washed twice
with PBS and harvested with trypsin-versene (CSL Biosciences,
Australia). Cells were counted by the Trypan blue exclusion
method using a haemocytometer and disrupted using a sonicator
(Ultrasonic Processor, USA). Three pulses of 30s were used to
sonicate cells with an interval of 30s in between. Erk-MAP kinase
assay was performed using an MAP kinase assay system
(Amersham, UK). The ability of cell-derived sonicates to transfer
phosphate from [g
32P] ATP to a synthetic peptide containing a
p42/44 MAP kinase-specific phosphorylation site was quantitated.
32P-labelled peptides were spotted onto PEI-cellulose paper,
nonpeptide bound radioactivity was removed by washing with
75mM phosphoric acid and bound
32P-labelled peptides were
measured by liquid scintillation counting. Protein estimation was
performed on each cell sonicate used and enzyme activity
calculated as described in the manufacturer’s instructions. Cell
lysates were also analysed by Western blotting. To test the effect of
uPA on Erk activation, subconfluent cultures of cells were serum-
starved overnight, washed and acid-stripped (0.05 M glycine-HCl in
0.1 M NaCl, pH 3) for 1min to remove uPAR-bound uPA. The pH
of the culture medium was neutralised quickly with two to three
washes of serum-free DMEM medium. The cells were incubated in
the presence of scuPA (20nM) for 30min. In some experiments, the
cells were treated with P25 peptide (100mM) for 1h before acid
stripping. Controls were treated with the scrambled version of the
peptide. In each case, the cell viability was checked by the Trypan
blue exclusion method and found to be 495%.
Preparation of conditioned medium
Conditioned medium was prepared as described previously
(Ahmed et al, 2002c). Briefly, exponentially growing adherent
cells were washed free of FBS and maintained in FBS-free medium.
After 48h, conditioned medium was concentrated 90–120-fold
using Biomax Ultrafree Centrifugal Filter Unit (Millipore, Bedford,
USA) with a 10-kDa pore diameter cutoff. In some experiments,
cells were treated with P25 peptide (100mM) for 48h. Control cells
contained equal concentration of the scrambled peptide. The
viability of cells was determined by Trypan blue exclusion method
and found to be 495%.
Western blotting
Conditioned medium and cell lysates containing equal amounts of
protein were electrophoresed on 10% SDS–PAGE gels under
nonreducing conditions and transferred to nitrocellulose mem-
branes. Membranes were probed with primary antibody followed
by peroxidase-labelled secondary antibody and visualised by the
(ECL) (Amersham, UK) detection system according to the
manufacturer’s instructions.
Zymography
Pro-MMP-2 and pro-MMP-9 expression in conditioned medium
was analysed using 10% SDS-gelatin (1mgml
 1 final concentra-
tion) zymography under nonreducing conditions as described
previously (Ahmed et al, 2002c). Gelatinolytic activity attributed
by MMP-2 and MMP-9 was confirmed by activation with APMA
(2mM) for 4h prior to zymography. Activation of pro-MMP-2 and
pro-MMP-9 could be abolished by incubating zymograms with
1:10 phenanthroline (2mM) or EDTA (data not shown).
Preparation and degradation of collagen type IV basement
membrane
HCT116 cell lines (WT, mock and A/S) were plated directly onto
the isotopically labelled collagen IV matrix at a density of 3 10
5
cellswell
 1 in 0.3ml serum-free medium as described previously
(Ahmed et al, 2002c). After 24h, the conditioned medium was
removed, centrifuged in a Beckman microfuge for 5min and
counted in a b-scintillation counter to monitor release of soluble
[
3H]-collagen fragments from the insoluble matrix. Matrix
degradation of the cells was measured by the release of [
3H]-
collagen in the medium. In studies involving inhibition of
plasminogen activation, uPA and MMP activity, cells were treated
with inhibitors, antibodies and peptides (P25 and Scp) 30min
prior to plating onto the [
3H]-collagen-labelled matrix. Cell
viability was checked by Trypan blue exclusion method and found
to be 495%.
Migration and invasion assay
The migratory and invasive response of HCT116 cell lines was
determined using Matrigel-coated invasion chambers (Becton and
Dickinson, USA). Approximately 2 10
5 cells were incubated in
Matrigel-coated inserts in serum free medium. Fetal bovine serum
(10%) was used as chemoattractant at 371C for 36h. Matrigel
inserts were removed and 0.5mCi of [
3H]-thymidine was added to
the cells in the wells for 12h. Cells were washed with PBS, dissolved
in 1% Triton and measured by liquid scintillation counting. The
migration and invasion of the cells was measured by [
3H]-
thymidine uptake of the cells migrating from the inserts into the
wells. In some experiments, cells were treated with peptides (P25
and Scp) in Matrigel inserts. Cell viability was checked by Trypan
blue exclusion method and found to be 495%.
Immunoprecipitation and coimmunoprecipitation
analyses
Monolayer cultures of HCT116 cell lines were washed twice with
PBS and harvested with trypsin-versene. To detect cell surface
expression of uPAR or b1 integrin, cells were biotinylated at 41C
for 40min and then lysed in lysis buffer (100mM Tris-HCl, pH 7.5,
150mM NaCl, 1mM CaCl2, 1% Triton X-100, 0.1% SDS, 0.1% NP-
40, 1mM vanadate, 1mg/ml
 1 pepstatin, 1mM PMSF, 5mgml
 1
Trasylol and 1mgml
 1 of leupeptin). The insoluble fraction of the
cell lysate was further solubilised in 1% Triton X-100. Total cells
lysates were immunoprecipitated with mAbs against uPAR (3936,
ADI) or b1 (PD52, Chemicon), or isotype-matched control.
Samples were resolved in 10% SDS–PAGE gel under nonreducing
conditions and were transferred to nitrocellulose membranes. In
case of biotinylation, membranes were probed with streptavidin–
HRP and then evaluated by ECL. In other cases, membranes were
probed with anti-uPAR or b1 integrin antibody followed by
peroxidase-labelled secondary antibody. ECL was used to detect
the protein bands. In some experiments, cell lysates were
immunodepleted of uPAR or b1 integrin after five rounds of
sequential uPAR or b1 immunoprecipitation.
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sStatistical methods
Student’s t-test was used for statistical analyses. Statistical
significance was indicated by Po0.05. Data are presented as
means7S.E.M.
RESULTS
Characterisation of untransfected and transfected HCT116
cells
To confirm the integration of antisensense uPAR cDNA into the
genome of the cells, Southern blot analyses were performed. As
shown in Figure 1 A parental (WT) and empty-vector-transfected
cells (mock) had three main bands of 9.22, 4.36 and 2.34kb (lanes
1 and 2). The antisense-transfected cells (A/S) revealed additional
bands of 2.2 and 1.3kb (lane 3). The extra bands hybridised to the
uPAR cDNA provided evidence of integration of one or more
copies of exogenous uPAR cDNA into the genome of the cells.
The patterns of cell surface expression of uPAR and b1 integrin
subunit on HCT116 clones were assessed by flow cytometry using
anti-uPAR and anti-b1 integrin antibody. The expression of cell
surface uPAR in WT and mock-transfected cells was two-fold
higher than in A/S clone, but there was no change in the expression
of b1 integrin (Figure 1B). There was no difference in the
proliferative response of mock- and A/S-transfected cells (Table 1).
The adhesive response of HCT116 clones was assessed on poly-L-
lysine, fibronectin and vitronectin. The suppression of uPAR
expression decreased the adhesion of A/S cells on poly-L-lysine by
1.3-fold (Table 1). Similar effects were observed on fibronectin or
vitronectin (data not shown).
Suppression of uPAR decreases activation of Erk MAP
kinase in HCT116 cells
As constitutive activation of Erk-MAP kinase has been implicated
with upregulation of uPAR in several human tumour types
(Hoshino and Kohno, 2000), we investigated whether p42/44
Erk-MAP kinase activity plays a role in the regulation of uPAR
expression in HCT116 cells. In vitro kinase assay, specific for p42/
44 MAP kinase activity, showed approximately two-fold higher
MAP kinase activity in WT and mock-transfected HCT116 cell
lines compared to A/S cell line (Table 2). Results from in vitro
kinase assay were consistent with Western blotting using
antibodies against phospho-Erk that showed inhibition of
phospho-Erk expression in A/S cell line (Figure 2A), but there
was no change in total immunoreactive Erk content as determined
by pan-Erk antibody (Figure 2B).
Suppression of uPAR correlates with decreased secretion
of HMW-uPA and abrogates the secretion of pro-MMP-9
into the conditioned medium
In order to evaluate a potential role of uPAR in the regulation of
proteolytic system, we examined the expression of HMW-uPA,
pro-MMP-2 and pro-MMP-9 in the conditioned medium from
HCT116 cell lines. Western blotting of conditioned medium with
equal protein loading showed approximately four-fold higher
expression of HMW-uPA in the conditioned medium of WT and
mock-transfected cells compared to that in A/S cells (Figure 3A).
Figure 1 Characterisation of HCT116 cells. (A) Southern blot analyses
of genomic DNAs isolated from transfected and untransfected HCT116
cells. Lane 1, WT HCT116 cells; lane 2, mock-transfected HCT116 cells;
and lane 3 is 50A/S HCT116 cells. (B) Flow-cytometric analyses of uPAR
and b1 integrin in HCT116 cell lines. The median intensity of fluorescence
(MIF, arbitary units, log scale) was measured. Results are representative of
three independent experiments.
"
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sGelatin zymography on conditioned medium showed high
expression of pro-MMP-9 in WT and mock-transfected HCT116
cells. Although A/S cell line showed high expression of pro-MMP-
2, the expression of pro-MMP-9 was absent (Figure 3B). Collec-
tively, these data demonstrated that the expression of uPAR
strongly correlates with elevated expression of the cell surface
proteinases.
Suppression of uPAR correlates with decreased migration/
invasion and plasminogen-dependent [
3H]-collagen IV
degradation
The possible correlation of uPAR expression with invasion and
extracellular matrix proteolysis was determined in WT, mock and
A/S HCT116 cell lines. For migration/invasion assay, invasion
chambers coated with Matrigel (Becton and Dickinson, MA, USA)
were used, while for matrix degradation [
3H]-collagen IV substrate
was chosen as substrate, as this molecule is the predominant
collagen type in the basement membrane and is the substrate for
both type IV collagenases (MMP-2 and MMP-9). WT and mock-
transfected cells showed four-fold greater migratory/invasive
capacity by Matrigel invasion assay compared to A/S cell lines
(Table 3). Even though the basal matrix degradation capacity in
the absence of Plg was approximately the same, the mock-
Table 1 Effect of uPAR suppression on the proliferative and adhesive
response of HCT116 cell lines
Cell type
MTT response
(absorbance at 595nm)
Adhesive response
(absorbance at 595nm)
HCT116 (mock) 1.5470.16 0.7470.04
HCT116 (A/S) 1.3470.22 0.5870.01*
Results are shown as mean7S.E.M of three different experiments performed in
triplicate. *Significantly different, Po0.002, compared to mock-transfected cells.
Table 2 Effect of uPAR suppression on the MAP kinase activity of
HCT116 cell lines
Cell type
MAP kinase activity
(pmolmin
 1mg
 1 of protein)
HCT116 (WT) 337741
HCT116 (mock) 290733
HCT116 (A/S) 140722*
Results are presented as mean7S.E.M of three different experiments performed in
triplicate. *Significantly different, Po0.001, compared to WT and mock-transfected
cell lines.
Figure 2 (A) Erk-MAP kinase activity in HCT116 cell lines. Cell lysates
used for in vitro kinase assay were analysed by equal protein loading on 10%
SDS–PAGE (under nonreducing conditions) followed by Western blotting
using antibodies against phosphorylated Erk-MAP kinase (E10 antibody,
New England Biolabs) and (B) total Erk (Santa Cruz, CA, USA).
Figure 3 (A) Expression of HMW-uPA in conditioned medium of WT,
mock- and A/S-transfected HCT116 cell lines. Conditioned medium was
analysed by equal protein loading on 10% SDS–PAGE (under nonreducing
conditions) followed by Western blotting using monoclonal anti-uPA
antibody. Ukidan was used as standard reference uPA (Serono, Australia).
The expression of HMW-uPA was quantified by densitometry and is
expressed as peak optical density (peak OD). Results are representative of
three experiments. (B) Gelatin zymography showing the amounts of pro-
MMP-2 and pro-MMP-9 secreted in conditioned medium (concentrated
90–100-fold) from HCT116 cell lines. The positions of purified pro-MMP-2
and pro-MMP-9 are shown on the left. Results are representative of three
independent experiments.
Table 3 Effect of uPAR suppression on the migration/invasion capacity
of HCT116 cell lines
Cell type [
3H]-thymidine uptake
HCT116 (WT) 3300798
HCT116 (mock) 3600788
HCT116 (A/S) 888748*
The migration and invasion of the cells were measured by [
3H]-thymidine uptake of
the cells migrating from the inserts into the wells. Results are shown as mean7S.E.M
of three different experiments performed in triplicate. *Significantly different,
Po0.001, compared to WT and mock-transfected cells.
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stransfected clone had a two-fold enhanced capacity to degrade
[
3H]-labelled collagen IV when plasminogen was present
(Table 4A). In contrast, the addition of Plg to A/S clone produced
no increase in the degradation of basement membrane. The two-
fold enhanced Plg-dependent collagen IV degradation seen in
mock HCT116 cell line was abolished by the addition of either uPA
inhibitor amiloride, the zinc chelator 1,10 phenanthroline, plasmin
inhibitor Trasylol and anti-uPAR antibody (Table 4B). These data
strongly suggest that in colon cancer uPA-mediated plasmin-
dependent serine and metalloproteolytic activity requisite for
matrix degradation coinside with high uPAR expression and can
be inhibited by blocking uPA/uPAR and plasmin mediated
pathways.
Suppression of uPAR impairs the uPA-induced Erk
activation in HCT116 cells
In cells, 80–90% of uPAR is occupied by endogenously produced
uPA (Ossowski, 1992), and uPA binds to uPAR to initiate signal
transduction (Nguyen et al, 1998). We tested whether or not the
addition of exogenous uPA had any affect on the signal to Erk
activation. Mock- and A/S-transfected HCT116 cells stripped of
endogenous uPA were incubated for 30min with uPA (20nM). uPA
induced a strong increase in phospho-Erk levels, while no such
stimulation was detected in A/S cells (Figure 4). These results
suggest that low level of Erk activation in A/S HCT116 cells is the
result of a reduced uPA/uPAR signalling capacity to endogenous
uPA.
a subunit integrin profile of mock- and A/S-transfected
HCT116 cells
As b1 integrin subunit binds with different a subunits, we wanted
to determine if suppression of uPAR expression had any effect on
the cell surface expression of a integrin subunits in HCT116
cell lines. The pattern of cell surface expression of a integrin
subunits was assessed using a panel of integrin-specific antibodies
(Table 5). Both cell lines expressed av, a2, a3 and a6 integrin
subunits. Suppression of uPAR had no effect on integrin subunit
expression.
Suppression of uPAR results in loss of uPAR/b1 integrin
complex
uPAR and b integrin interaction result in integrin activation in
leucocytes during in vivo transendothelial migration (May et al,
1998) and in modulating integrin function as adhesion receptors in
293 kidney and ovarian cancer cells (Wei et al, 1996; Hapke et al,
2001). Therefore, we tested whether change in adhesion and
invasive function of A/S HCT116 cells due to 50% reduction in
uPAR expression had any effect on uPAR/b1 interaction. We first
examined whether uPAR and b1 integrin were physically
associated by testing the ability of anti-b1 antibody to coimmu-
noprecipitate (co-IP) uPAR and of uPAR antibody to co-IP b1
integrin from cell lysates. In mock-transfected HCT116 cells,
immunoprecipitates (IPs) of b1 integrin and uPAR revealed a
complex that was absent in A/S cells reflecting, most likely, the low
levels of uPAR in these cells (Figures 5A,B). Even though, both
mock-and A/S-transfected cells contained similar amounts of b1
integrin (Figure 1B) interacting band with uPAR was drastically
diminished in A/S cell line. In another approach, cells were
biotinylated before immunoprecipitation with b1 integrin antibody.
In mock-transfected cells, anti-b1 antibody coimmunoprecipitated
bands at 50 and 120kDa corresponding to uPAR and b1 integrin
respectively (Figure 5C) (two unidentified bands at 90–100 and
75–80kDa were also present). On the other hand, b1 integrin IP in
A/S cells showed b1 integrin corresponding band, but the band
corresponding to uPAR was reduced dramatically (Figure 5C). The
absence of other unidentified bands at 75–80 and 90–100kDa in
b1 integrin IP of A/S-transfected cells indicates that downregulation
of uPAR results in loss of complex formed by b1 integrin with other
proteins. The identity of uPAR and b1 integrin interaction was
Table 4A Effect of uPAR suppression on [
3H]-collagen IV degradation in
HCT116 cell lines
Matrix degradation (CPM/3 10
5 cells)
Cell type  Plg +Plg
HCT116 (mock) 275732 600756*
HCT116 (A/S) 264730 308722
Matrix degradation of the cells was measured by the release of [
3H]-collagen IV in the
medium. Results are shown as mean7S.E.M of three different experiments
performed in triplicate. *Significantly different, Po0.001, compared to control cells
in the absence of Plg.
Table 4B Effect of uPA, MMPs and plasmin inhibitors on the matrix
degradation of mock-transfected HCT116 cell line
Cell treatment
Matrix degradation
(CPM/3 10
5 cells)
 Plg 275732
+Plg 600756
+Plg+DMSO 586737
+Plg+amiloride (2mM) 263742*
+Plg+phenanthroline (2mM) 260733*
+Plg+Trasylol (10mgml
 1) 270730*
+Plg+IgG2a (10mgml
 1) 586760
+Plg+anti-uPAR (10mgml
 1) 426740*
Matrix degradation of the cells was measured by the release of [
3H]-collagen IV in the
medium. Results are shown as mean7S.E.M of three different experiments
performed in triplicate. *Significantly different, Po0.001, compared to control cells
in the presence of Plg.
Figure 4 Effect of uPA on the activation of Erk. Subconfluent cultures of
mock and A/S HCT116 cells were serum starved for 24h, acid stripped for
1min and incubated with uPA (20nM) for 30min. The level of phospho
Erk1/2 was determined by Western blot using equal protein loading.
Results are representative of one experiment. The experiment was
repeated three times.
Table 5 Cell surface expression at a integrin subunits in mock and A/S
HCT116 cell lines
Cell type
a2 integrin
MIF
a3 integrin
MIF
a6 integrin
MIF
av integrin
MIF
HCT116 (mock) 164 225 23 48
HCT116 (A/S) 184 224 20 60
MIF¼mean intensity of fluorescence.
Antisense uPAR inhibits colon cancer invasiveness
N Ahmed et al
379
British Journal of Cancer (2003) 89(2), 374–384 & 2003 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
sverified further in mock-transfected HCT116 cells by immunode-
pleting the cell lysates of b1 integrin (Figures 5D and 5E) or
uPAR (Figure 5E) by five rounds of immunodepletion steps.
This resulted in loss of uPAR or b1 integrin interacting band
indicating that uPAR directly interacts with b1 integrin in HCT116
cells.
Functional role of uPAR/b1 integrin complex in
mock-transfected HCT116 cells
The functional role of uPAR/b1 integrin complex in terms of
migration/invasion and matrix degradation was studied in HCT116
cells using a 17-amino-acid peptide sequence (P25) at 100mM
Figure 5 Coimmunoprecipitation of b1 integrin and uPAR. Mock- and A/S-transfected HCT116 cells were lysed in Triton X-100 buffer (see Materials and
Methods). Cell protein (500mg) was mixed with anti-b1 antibody (PD52) or anti-uPAR antibody (3936) or isotype-matched mouse IgG and the resulting
immunoprecipitates were analysed by Western blotting with (A) anti-b1-integrin antibody (PD52) or (B) anti-uPAR antibody (3936). (C) Cells were
surface biotinylated and cell extracts were subjected to immunoprecipitation with anti-b1 antibody or with isotype-matched IgG antibodies and analysed by
streptavidin–HRP binding to biotinylated proteins after SDS–PAGE and transfer to nitrocellulose membranes. (D and E) Mock-transfected cell lysates were
immunodepleted (ID)of b1 after five rounds of sequential b1 and uPAR immunoprecipitation. Cell lysates were resolved by 10% SDS–PAGE followed by
blotting with (D) anti-uPAR and (E) anti-b1 integrin antibody. The experiments were repeated at least three times.
Figure 6 uPAR/b1 integrin complex and the affect of P25 peptide. (A) P25 peptide but not scrambled peptide (Scp) disrupts uPAR/b1 integrin complex
in mock-transfected HCT116 cells. Cells were treated for 16h with P25 peptide (100mM) and Scp (100 mM). Immunoprecipitates of uPAR were prepared
and coimmunoprecipitated b1 integrin band was analysed. (B) Migration/invasion of HCT116 mock cells in the presence of P25 peptide and its scrambled
analogue (100mM each). (C) Plasminogen-dependent matrix degradation of HCT116 mock cells in the presence of P25 peptide and its scrambled analogue
(100mM each). Results for both Figures 6B and C are shown as mean þ s.e.m. of three different experiments performed in triplicate (*Po0.001, compared
to control cells in the presence of Plg). (D) Effects of P25 peptide and its scrambled analogue on the secretion and activation of pro-MMP-2/MMP-9.
Conditioned medium in the presence and absence of Plg, P25 peptide and Scp (100mM each) was prepared as described in the Materials and Methods
section. The samples were analysed by equal protein loading by gelatin-zymography for the activation of pro-MMP-2/MMP-9. Quantification of MMP
secretion in the tumour-conditioned medium was performed by densitometry and the results are expressed as peak OD. Results are representative of one
experiment. The experiment was repeated three times. (E) Effect of P25 peptide and its scrambled analogue (100mM each) on uPA-induced activation of
Erk in mock-transfected HCT116 cells. Subconfluent cultures of mock-transfected HCT116 cells were serum starved for 24h, acid stripped for 1min and
incubated with uPA (20nM) for 30min. The level of phospho Erk1/2 was determined by Western blot using equal protein loading. Quantification of
phospho Erk1/2 expression was performed by densitometry and expressed as peak OD. Results are representative of one experiment. The experiment was
repeated three times.
"
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sconcentration, a concentration that has been shown to disrupt
specifically uPAR/b1 integrin complexes without affecting ligand
binding of both receptors (Wei et al, 1996). In mock-transfected
HCT116 cells, P25 peptide (100mM) disrupted uPAR/b1 integrin
complex as shown by the loss of b1 interacting band in uPAR IP
(Figure 6A). P25 peptide (100mM) also inhibited migration/
invasion (Figure 6B) and plasmin-mediated collagen IV degrada-
tion (Figure 6C) through suppression of pro-MMP-9 (three-fold)
and pro-MMP-2 (seven-fold) secretion and lack of activation of
plasmin-mediated pro-MMP/2 (Figure 6D).
We determined if uPA-mediated activation of Erk-MAP kinase
signalling through uPAR/b1 integrin complex is required for pro-
MMP-2/MMP-9 secretion and subsequent invasion and plasmin-
mediated matrix degradation. Mock-transfected cells were acid
stripped of endogenous uPA and then stimulated with uPA (20nM)
for 30min in the presence of P25 peptide and its scrambled
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sanalogue. In control and Scp-treated cells, uPA induced 2.5-fold
enhancement of Erk activation compared to only 1.6-fold in the
presence of P25 peptide. Hence, P25 peptide, but not its scrambled
analogue was able to inhibit uPA-induced activation of Erk
(Figure 6E) suggesting that functional uPAR/b1 complex is
required for optimum endogenous uPA-mediated Erk activation
essential for plasmin-mediated matrix degradation.
DISCUSSION
Previous reports have shown that suppression of cell surface uPAR
expression induces a dormancy in carcinoma cells characterised by
cancer cell survival but unaccompanied by increase in tumour
mass (Yu et al, 1997). Recently, we have demonstrated inhibition
of metastatic capability of colon cancer HCT116 cell line in vivo by
inhibition of uPAR expression by an antisense method (Wang et al,
2001). This outcome is possibly due to reduced signalling by uPA
through uPAR expressed below the threshold limit required to
initiate an outside-in signalling cascade capable of maintaining the
cancer cells in a proliferative and invasive state (Aguirre Ghiso
et al, 1999b). Results reported here further develop this paradigm
by elucidating the specificity of uPAR and b1 integrin interaction
in terms of uPA/plasmin-mediated activation and subsequently
matrix degradation. Our results demonstrate that downregulation
of uPAR expression by an antisense approach in a colon cancer cell
line was associated with a two-fold inhibition of Erk-MAP kinase
pathway, inhibition of uPA secretion, complete inhibition of pro-
MMP-9 secretion, 1.3-fold inhibition in adhesion, four-fold
inhibition in migratory/invasive capacity and complete abrogation
of plasmin-dependent matrix degradation. uPAR-suppressed cells
have reduced uPA/uPAR signalling capacity and they lack the
capacity to elicit Erk phosphorylation in response to low
concentration of uPA. In mock-transfected uPAR-rich cells, uPAR
interacts with b1 integrin and that interaction is drastically
reduced in uPAR-suppressed A/S cells. We also demonstrate that
uPAR/b1 integrin complex initiate signalling pathways promoting
matrix degradation, as disruption of this complex results in
suppression of pro-MMP-9/MMP-2 secretion and lack of activa-
tion of plasmin-mediated pro-MMP-2, resulting in total abrogation
of matrix degradation. To our knowledge, this is the first study to
report links between uPAR/b1 integrin complex, Erk signalling
pathway and the expression and activation of metalloproteinases
leading to matrix degradation.
There is abundant evidence in the literature indicating that uPA/
uPAR interaction activates the Erk pathway (Ossowski and
Aguirre-Ghiso, 2000). The cell type where these pathways are
activated may have different biological outcomes such as
migration and motility, growth and differentiation, etc. (Yebra
et al, 1996; Stepanova et al, 1997; Dumler et al, 1999; Ferrero et al,
2000). As the binding of uPA to uPAR is critical for the activation
of Erk, we can hypothesise that high level of endogenous uPA
expressed and secreted by WT and mock-transfected HCT116 cells
can bind to excess uPAR on the cell surface, and thereby regulate
the steady-state level of active Erk. The fact that a low
concentration of uPA induces a strong increase in active Erk
levels in acid-stripped uPAR-rich mock-transfected cells while no
such effect can be seen in uPAR-reduced A/S cells support this
assumption and suggest that down regulation of uPAR-expression
in cancer cells reduces the ability of the cells to initiate uPA-
mediated Erk signalling. Our observations are consistent with
those of Aguirre Ghiso et al. (1999b) who showed lack of
responsiveness of human carcinoma Hep3 cells to uPA when cell
surface expression of uPAR was reduced by 70%. Similarly, Webb
et al (2000) showed that neutralisation of receptors in LDL
receptor family (LRF) leads to inhibition of catabolism of uPA and
uPAR, resulting in increased binding of endogenously produced
uPA to uPAR and the enhancement of basal level of activated Erk.
Moreover, recently it has been shown that endogenously produced
uPA is a major determinant of the basal level of activated Erk in an
aggressive breast cancer cell line (Ma et al, 2001). Hence, the ability
of uPA/uPAR system to sustain elevated basal level of activated Erk
may represent a mechanism whereby uPA/uPAR system may affect
cancer progression and distant metastasis in vivo.
Our study also demonstrates that downregulation of uPAR
abrogates plasminogen-dependent matrix degradation in low
uPAR-expressing A/S HCT116 cells. Inhibition of Erk-MAP kinase
pathway has been shown to affect the expression of serine
proteinase uPA (De Kier Joffe et al, 2000) and metalloproteinase
MMP-9 (Cho et al, 2000). We have recently shown that activation
of Erk is critical for plasminogen-dependent matrix degradation
mediated by pro-uPA and pro-MMP-9 (Ahmed et al, 2002b). Since,
activation of MMPs by plasminogen occurs through uPA-
dependent plasmin generation (Ramos-DeSimone et al, 1999), it
can be suggested that enhanced expression of uPAR is critical for
sustaining basal level of activated Erk requisite for the secretion of
pro-MMPs and plasminogen-mediated activation of the protei-
nases in colon cancer cells.
As uPAR lacks the transmembrane signalling domain, we
explored the involvement of b1 integrin as a possible ‘adapter
molecule’ capable of initiating signalling of uPA through uPAR.
We show that uPAR physically interacts with b1 integrin in uPAR-
rich mock-transfected HCT116 cells and that interaction is
significantly diminished in low uPAR-expressing A/S cells. The
expression of b1 integrin and its associated av, a2, a3 and a6
subunits remain unchanged with the downregulation of uPAR
expression in A/S-transfected cells. Hence, one can postulate that it
is not the integrin expression itself but its association with uPAR
and other interacting molecules (caveolin, src kinases, nucleolin,
casein kinase 2, etc.) that may affect phenotypic differences
between the cell lines. Consistent with that, the activation of Erk-
MAP kinase cascade has been shown to be generated by the
combined effect of uPA/uPAR/b1 integrin complex if uPAR
expression exceeds a certain threshold limit (Aguirre Ghiso et al,
1999b). If the interaction is diminished as in the case of
downregulation of uPAR by antisense treatment or interrupted
by inhibitors, the signalling complex is turned off. This is
consistent with the effect of P25 peptide on Erk activation, pro-
MMP-2/MMP-9 secretion and inhibition of matrix degradation.
Hence, one can suggest that lateral interaction between uPAR and
b1 integrin in uPAR-rich cells may render Erk pathway
constitutively active to maintain the expression of proteases
required for the invasive phenotype of cancer cells. Hence, we
can hypothesise that uPAR-rich colon cancer cells endogenously
produces its ligand uPA to sustain elevated level of Erk-MAP
kinase pathway through uPAR/b1 integrin complex. Considering
that elevated level of uPAR is associated with negative prognosis of
colon cancer (Ganesh et al, 1994) and is observed in invasive colon
tumours (Ganesh et al, 1994; Wang, 2001), the impact of uPAR/b1
integrin complexes in colon cancer invasion and metastasis needs
to be evaluated. To the best of our knowledge, ours is the first
study to report the mechanism(s) of invasiveness of cancer cells
through uPA/uPAR/integrin binding.
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